Cagrilintide & Semaglutide Blend (10mg)

This 10mg blend combines Cagrilintide 5mg and Semaglutide 5mg in a single vial, both peptides synthesized and lyophilized in the USA. Each batch is purified by multiple rounds of HPLC and confirmed by mass spectrometry, with purity above 99% and third-party certificates published for every lot. For in-vitro laboratory research use only.

Each vial of Cagrilintide & Semaglutide Blend (10mg) contains a pre-weighed ratio of Cagrilintide 5mg, Semaglutide 5mg in a single lyophilized cake, simplifying multi-peptide research protocols.

Researchers using Cagrilintide & Semaglutide Blend (10mg) often combine dose-response assays with stability testing to establish reproducible experimental baselines.

Interest in Cagrilintide & Semaglutide Blend (10mg) has grown alongside comparative work on incretin-related pathways and substrate utilization in cultured systems.

Cagrilintide & Semaglutide Blend (10mg) serves as a research tool for examining the interplay between peptide signaling and metabolic endpoints in experimental designs.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with Cagrilintide & Semaglutide Blend (10mg). Summaries are provided for orientation only and reflect the cited sources.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial^[1] — This phase 1b randomized controlled trial examined the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of cagrilintide co-administered with semaglutide 2.4 mg in the context of weight management. The authors reported that the combination was tolerated across the tested dose levels and generated supportive data for the dual-agonist approach. These findings laid early groundwork for the clinical development of the cagrilintide–semaglutide combination as a weight-management therapy. (Lancet (London, England) 2021)

Development of Cagrilintide, a Long-Acting Amylin Analogue^[2] — This medicinal chemistry report describes the discovery and development of cagrilintide, a long-acting acylated analogue of amylin designed to extend the duration of action of the native hormone. The authors detail the structure–activity optimization that yielded a peptide with prolonged pharmacokinetic properties. The work underpins the rationale for using cagrilintide as a sustained amylin-based component in combination weight-management strategies. (Journal of medicinal chemistry 2021)

Once-Weekly Semaglutide in Adults with Overweight or Obesity^[3] — This landmark phase 3 trial evaluated once-weekly subcutaneous semaglutide versus placebo in adults with overweight or obesity without diabetes. The study reported substantial weight reduction in the semaglutide group, establishing the efficacy of the GLP-1 receptor agonist for body-weight management. The results support the semaglutide component of combination products such as the cagrilintide–semaglutide blend. (The New England journal of medicine 2021)

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes^[4] — This cardiovascular outcomes trial assessed once-weekly semaglutide in patients with type 2 diabetes at high cardiovascular risk. The authors reported a lower rate of major cardiovascular events with semaglutide compared with placebo over the study period. These findings established the cardiovascular profile of semaglutide that underlies its continued use in metabolic therapies. (The New England journal of medicine 2016)

References

1. Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial." Lancet (London, England). 2021. pubmed.ncbi.nlm.nih.gov/33894838/
2. Kruse T, Hansen JL, Dahl K, Schäffer L, Sensfuss U, Poulsen C, Schlein M, Hansen AMK, Jeppesen CB, Dornonville de la Cour C, Clausen TR, Johansson E, Fulle S, Skyggebjerg RB, Raun K. "Development of Cagrilintide, a Long-Acting Amylin Analogue." Journal of medicinal chemistry. 2021. pubmed.ncbi.nlm.nih.gov/34288673/
3. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." The New England journal of medicine. 2021. pubmed.ncbi.nlm.nih.gov/33567185/
4. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T, SUSTAIN-6 Investigators. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." The New England journal of medicine. 2016. pubmed.ncbi.nlm.nih.gov/27633186/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.